Pittsburgh, PA (PRWEB) June 25, 2012
invivodata inc. ® the industry leader in reliable electronic solutions and strategic consulting services for successful Clinical Outcome Assessment (COA) data collection in global clinical research, today announced that it’s president and CEO Doug Engfer, has been selected as a finalist for the Ernst & Young Entrepreneur Of The Year Award in the Western Pennsylvania and West Virginia area. The annual awards program recognizes entrepreneurs who demonstrate excellence and extraordinary success in areas including innovation, financial performance and personal commitment to their businesses and communities.
Ernst & Young’s Entrepreneur of the Year Award is the world’s most prestigious business award for entrepreneurs. The unique award makes a difference through the way it encourages entrepreneurial activity among those with potential, and recognizes the contribution of people who inspire others with their vision, leadership and achievement. The program is significant because it honors and recognizes men and women who create the products, services and jobs that help our economy and communities grow.
“I’m deeply honored to receive this recognition and consider it a milestone accomplishment for invivodata,” said Doug Engfer. “Our record growth over the past few years is the direct result of our employees’ hard work and commitment to delivering the best COA data for our customers’ clinical development programs.”
invivodata is the only fully-integrated Clinical Outcomes Assessments (COA) company delivering regulatory-proven strategic consulting and practical electronic solutions to biopharmaceutical companies who depend upon patient-centered research. From reliable and scientifically sound consulting that helps research teams effectively develop, execute, and document COA strategies to electronically collecting COA data in global clinical development programs, invivodata helps its customers strategically use patient, clinician, and observer reported outcomes data (PROs, ClinROs & ObsROs) to support labeling claims, enhance reimbursement strategies, and meet other clinical program objectives. Through partnerships with leading CROs and eClinical technology providers, invivodata seamlessly integrates into the clinical trial ecosystem, helping to minimize operational risk and maximize efficiencies. invivodata’s electronic solutions and strategic consulting services have been used in over 600 clinical projects and are built upon the industry-leading ePRO system in delivering primary efficacy data for global drug approvals. invivodata, inc. is a privately held company with global headquarters in Pittsburgh, PA., USA; its European headquarters is in London, England; and its technology development center is in Scotts Valley, CA., USA. For more information, visit http://www.invivodata.com